Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome
P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).
- To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses.
Secondary Objectives:
- To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in
Segment 1
- To characterize the safety and tolerability of 28-day consecutive doses of 500 mg
SAR302503 in Segment 2
- To determine antitumor activity in Segment 2